| abstract |
The present invention treats a disease mediated by CD47 or a phagocytic action or a novel CD47 antibody or immunologically active fragment thereof, which has low immunogenicity in humans and causes little or no red blood cell depletion or red blood cell aggregation. Provided is a pharmaceutical composition comprising the aforementioned antibody that can be used to inhibit platelet aggregation. |